Coley Pharmaceutical Group, Inc. 4
4 · Coley Pharmaceutical Group, Inc. · Filed Aug 17, 2005
Insider Transaction Report
Form 4
Caspritz Gert
Director
Transactions
- Conversion
Series F Convertible Preferred Stock
2005-08-15−4,305,169→ 0 total(indirect: Interests held by TVM IV GmbH KG and TVM V Life Science Ventures GmbH KG)Exercise: $0.25From: 2005-08-15Exp: 2005-08-15→ Common Stock (1,086,615 underlying) - Conversion
Series A Convertible Preferred Stock
2005-08-15−3,000→ 0 totalExercise: $0.22From: 2005-08-15Exp: 2005-08-15→ Common Stock (655 underlying) - ConversionSwap
Common Stock
2005-08-15+1,086,615→ 1,086,615 total(indirect: Interests held by TVM IV GmbH KG and TVM V Life Science Ventures GmbH KG) - Conversion
Series G Convertible Preferred Stock
2005-08-15−3,404,278→ 0 total(indirect: Interests held by TVM V Life Science Ventures GmbH KG)Exercise: $0.22From: 2005-08-15Exp: 2005-08-15→ Common Stock (743,292 underlying) - ConversionSwap
Common Stock
2005-08-15+655→ 4,221 total - ConversionSwap
Common Stock
2005-08-15+743,292→ 743,292 total(indirect: Interests held by TVM V Life Science Ventures GmbH KG)
Footnotes (4)
- [F1]The shares of Series A Convertible Preferred Stock converted automatically to Common Stock upon the completion of the Issuer's initial public offering on August 15, 2005.
- [F2]The shares of Series F Convertible Preferred Stock converted automatically to Common Stock upon the completion of the Issuer's initial public offering on August 15, 2005.
- [F3]The shares of Series G Convertible Preferred Stock converted automatically to Common Stock upon the completion of the Issuer's initial public offering on August 15, 2005.
- [F4]Mr. Caspritz disclaims beneficial ownership except to the extent of his pecuniary interest.